Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.40 |
| ▸ | ELANE | P08246 | 6/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | SCN2B | O60939 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083571 | 0.90 | HPGDS (0.58) | HPGDSGRIN2BSCN2BSCN1ASCN1B | |
| SCHEMBL14313000 | 0.87 | HPGDS (0.48) | HPGDSGRIN2BELANEGRIN1SCN2B | |
| SCHEMBL12084264 | 0.85 | HPGDS (0.53) | HPGDSGRIN2BSCN2BSCN1ASCN1B | |
| SCHEMBL12083580 | 0.83 | HPGDS (0.58) | HPGDSSCN2BSCN1BSCN9A | |
| SCHEMBL3227794 | 0.83 | HPGDS (0.66) | HPGDSSCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL12083696 | 0.79 | HPGDS (0.78) | HPGDSSCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL12083584 | 0.78 | HPGDS (0.74) | HPGDSSCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL14313139 | 0.77 | HPGDS (0.52) | HPGDSSCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL12083828 | 0.76 | HPGDS (0.55) | HPGDSSCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL12083557 | 0.76 | HPGDS (0.46) | HPGDSSCN2BSCN1ASCN1BSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HPGDS 10/4885GRIN2B 770/4885ELANE 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.